1.

Disease: Lung Cancer
Drug Name: Pembrolizumab
Phase: II
Duration: 18 months
Summary / Protocol: Assessing the efficacy and safety of Pembrolizumab in patients with advanced non-small cell lung cancer. Primary endpoints include progression-free survival and overall response rate.

---

2.

Disease: Type 2 Diabetes
Drug Name: Semaglutide
Phase: III
Duration: 24 months
Summary / Protocol: Evaluating the long-term glycemic control and cardiovascular outcomes of Semaglutide in adults with Type 2 Diabetes. Secondary endpoints include weight reduction and HbA1c levels.

---

3.

Disease: Breast Cancer
Drug Name: Trastuzumab
Phase: I
Duration: 12 months
Summary / Protocol: Determining the safety, tolerability, and optimal dosing of Trastuzumab in HER2-positive breast cancer patients. Endpoints include dose-limiting toxicities and pharmacokinetics.

---